Treatment of chronic viral hepatitis in patients with renal disease

Gastroenterology Clinics of North America

Volumn 33, Issue 3, 2004, Pages 655-670

  Fabrizi, Fabrizio ^a,b   Martin, Paul ^a   Bunnapradist, Suphamai ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; CYCLOPHOSPHAMIDE; LAMIVUDINE; PEGINTERFERON; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN;

CHRONIC DISEASE; CLINICAL TRIAL; DIALYSIS; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; GLOMERULONEPHRITIS; GRAFT INFECTION; HEMOLYTIC ANEMIA; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INFECTION RISK; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LIVER BIOPSY; RANDOMIZATION; REVIEW; SIDE EFFECT; TREATMENT INDICATION; VIRUS VIRULENCE;

ANTIVIRAL AGENTS; CRYOGLOBULINEMIA; GLOMERULONEPHRITIS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; RENAL DIALYSIS;

EID: 8444237788     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2004.04.011     Document Type: Review

References (40)

1. Tokars J., Frank M., Alter M., et al. National surveillance of dialysis-associated diseases in the United States, 2000. Semin Dial. 15:(3):2002;162-171
2. Lee B.W., Yap H.K., Tan M., et al. Cell-mediated immunity in patients on hemodialysis: relationship with hepatitis B carrier status. Am J Nephrol. 11:(2):1991;98-101
3. Guh J., Lai Y., Yang C., et al. Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients. Nephron. 69:(4):1995;459-465
4. Nakayama E., Akiba T., Marumo F., et al. Prognosis of antihepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol. 11:(10):2000;1896-1902
5. Fabrizi F., Poordad F.F., Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 36:(1):2002;3-10
6. Fabrizi F., Martin P., Ponticelli C. Hepatitis B virus and renal transplantation. Nephron. 90:(3):2002;241-251
7. Natov S., Lau J., Ruthazer R., et al. Hepatitis C virus genotype does not affect patient survival among renal transplant candidates. The New England Organ Bank Hepatitis C Study Group. Kidney Int. 56:(2):1999;700-706
8. Pereira B., Natov S., Bouthot B., et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int. 53:(5):1998;1374-1381
9. Mathurin P., Mouquet C., Poynard T., et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 29:(1):1999;257-263
10. Fabrizi F., Lunghi G., Martin P. Recent advances in the management of hepatitis C in the dialysis population. Int J Artif Organs. 25:(6):2002;503-511
11. Huraib S., Iqbal A., Tanimu D., et al. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic viral hepatitis C. Am J Nephrol. 21:(6):2001;435-440
12. Rostaing L., Chatelut E., Payen J.L., et al. Pharmacokinetics of alfa IFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol. 9:(12):1998;2344-2348
13. Bruchfeld A., Stahle L., Andersson J., et al. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection - a pilot study. J Viral Hepat. 8:(4):2001;287-292
14. Tan A.C., Brouwer J.T., Glue P., et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant. 16:(1):2001;193-195
15. Martin P., Mitra S., Farrington K., et al. Pegylated(40KDA) interferon alfa-2A(Pegasys) is unaffected by renal impairment. Hepatology. 32:(2):2000;842
16. Lamb M., Marks I., Wynohradnyk L., et al. 40 Kda Peginteferon alfa-2A(Pegasys) can be administered safely in patients with end-stage renal disease. Hepatology. 34:(4):2001;34-190
17. Fabrizi F., Martin P., Ponticelli C. Hepatitis C virus infection and renal transplantation. Am J Kidney Dis. 38:(5):2001;919-934
18. Baid S., Tolkoff-Rubin N., Saidman S., et al. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant. 3:(1):2003;74-78
19. Garnier J.L., Chevallier P., Dubernard J.M., et al. Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients. Transplant Proc. 29:1997;783
20. Rostaing L. Treatment of hepatitis C virus infection after renal transplantation: new insights. Nephrology Dialysis Transplantation. 15:(Suppl 8):2000;74-76
21. Casanovas-Taltavull T., Baliellas C., Benasco C., et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol. 96:(4):2001;1170-1177
22. Campistol J.M., Esforzado N., Martinez J., et al. Efficacy and tolerance of interferon-alfa(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrology Dialysis Transplantation. 14:(11):1999;2704-2709
23. Tokumoto T., Tanabe K., Ishikawa N., et al. Effect of interferon-alfa treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C. Transplant Proc. 31:(7):1999;2887-2889
24. Bunnapradist S., Fabrizi F., Vierling J., et al. Hepatitis C therapy with long-term remission after renal transplantation. Int J Artif Organs. 25:(12):2002;1189-1193
25. Cruzado J., Casanovas-Taltavull T., Torras J., et al. Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant. 3:(3):2003;357-360
26. Duarte R., Huraib S., Said R., et al. Interferon-alfa facilitates renal transplantation in hemodialysis patients with chronic viral hepatitis. Am J Kidney Dis. 25:(1):1995;40-45
27. Fontaine H., Thiers V., Chretien Y., et al. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation. 69:(10):2000;2090-2094
28. Chan T.M., Fang G.X., Tang C.S., et al. Pre-emptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology. 36:(5):2002;1246-1252
29. Park S., Yang W., Lee Y., et al. Outcome of renal transplantation in hepatitis B surface antigen-positive patients after introduction of lamivudine. Nephrology Dialysis Transplantation. 16:(11):2001;2222-2228
30. Fabrizi F., Colucci P., Ponticelli C., et al. Kidney and liver involvement in cryoglobulinemia. Semin Nephrol. 22:(4):2002;309-318
31. Misiani R., Bellavita P., Fenilli D. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C infection. N Engl J Med. 330:1994;751-756
32. Johnson R., Gretch D., Couser W. Hepatitis C virus-associated glomerulonephritis. Kidney International. 46:1994;1700-1704
33. Misiani R., Bellavita P., Baio P., et al. Successful treatment of HCV-associated cryoglobulinaemic glomerulonephritis with a combination of interferon-alpha and ribavirin. Nephrology Dialysis Transplantation. 14:(6):1999;1558-1560
34. Quigg R.J., Brathwaite M., Gardner D.F., et al. Successful cyclophosphamide treatment of cryoglobulinemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection. Am J Kidney Dis. 25:(5):1995;798-800
35. Gilli P., Stabellini N., Storari A., et al. Effect of human leukocyte alpha interferon on cryoglobulinaemic membranoproliferative glomerulonephritis associated with hepatitis C virus infection. Nephrology Dialysis Transplantation. 11:(3):1996;526-528
36. Sarac E., Bastacky S., Johnson J.P. Response to high-dose interferon-alfa after failure of standard therapy in MPGN associated with hepatitis C virus infection. Am J Kidney Dis Jul. 30:(1):1997;113-115
37. Garini G., Allegri L., Carnevali L., et al. Interferon-alfa in combination with ribavirin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis. Am J Kidney Dis. 38:(6):2001;E35
38. Reed M.J., Alexander G.J., Thiru S., et al. Hepatitis C-associated glomerulonephritis - a novel therapeutic approach. Nephrology Dialysis Transplantation. 16:(4):2001;869-871
39. Dussol B., Moal V., Daniel L., et al. Spontaneous remission of HCV-induced cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant Jan. 16:(1):2001;156-159
40. Rosenstock J.L., Stern L., Sherman W.H., et al. Fludarabine treatment of cryoglobulinemic glomerulonephritis. Am J Kidney Dis. 40:(3):2002;644-648